Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 18/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5664036 | 1.00 | CCR3 (0.44) | CCR3MAPTRAB9ACYP2D6DRD2 | |
| SCHEMBL4428998 | 1.00 | CCR3 (0.44) | CCR3MAPTRAB9ACYP2D6DRD2 | |
| SCHEMBL4426694 | 0.89 | HTT (0.43) | CCR3CYP2D6DRD2SLC6A2HTR2A | |
| SCHEMBL14368998 | 0.89 | HTT (0.43) | CCR3CYP2D6DRD2SLC6A2HTR2A | |
| SCHEMBL5659781 | 0.89 | CCR3 (0.52) | CCR3CYP2D6DRD2SLC6A2HTR2A | |
| SCHEMBL14392548 | 0.89 | CCR3 (0.52) | CCR3CYP2D6DRD2SLC6A2HTR2A | |
| SCHEMBL4428303 | 0.87 | CCR3 (0.46) | CCR3CYP2D6DRD2SLC6A2HTR2A | |
| SCHEMBL14392359 | 0.86 | CCR3 (0.48) | CCR3CYP2D6DRD2SLC6A2HTR2A | |
| SCHEMBL14369133 | 0.86 | CCR3 (0.48) | CCR3CYP2D6DRD2SLC6A2HTR2A | |
| SCHEMBL4431718 | 0.86 | CCR3 (0.48) | CCR3CYP2D6DRD2SLC6A2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101484442-A | Compounds that are agonists of muscarinic receptors and tha may be effective in treating pain, alzheimer's disease and/or schizophrenia | ASTRAZENECA AB (SE) | 2009-07-15 | — | — | CN | disclosed |
| EP-2024359-A1 | COMPOUNDS THAT ARE AGONISTS OF MUSCARINIC RECEPTORS AND THAT MAY BE EFFECTIVE IN TREATING PAIN, ALZHEIMER'S DECEASE AND/OR SCHIZOPHRENIA | AstraZeneca AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007126362-A1 | COMPOUNDS THAT ARE AGONISTS OF MUSCARINIC RECEPTORS AND THAT MAY BE EFFECTIVE IN TREATING PAIN, ALZHEIMER'S DISEASE AND/OR SCHIZOPHRENIA | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | WO | disclosed |
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259888-A1 | Novel Compounds | OPRL1, OPRM1, SIGMAR1 | CCR3 247/4885MAPT 2686/4885RAB9A 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.